Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?
/in Dendritic Cells, International Publications, Ovarian CancerCytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial
/in Dendritic Cells, International Publications, Malignant MelanomaCurcumin effect on cancer cells‘ multidrug resistance: An update
/in Curcuma, International PublicationsEfficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial
/in Curcuma, International PublicationsCellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment
/in Dendritic Cells, International PublicationsA moderate thermal dose is sufficient for effective free and TSL based thermochemotherapy
/in Hyperthermia, International PublicationsVaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 conventional dendritic cells
/in Dendritic Cells, International PublicationsPotentiation of the Abscopal Effect by Modulated Electro-Hyperthermia in Locally Advanced Cervical Cancer Patients
/in Cervical Cancer, Hyperthermia, International PublicationsDendritic cell therapy in cancer treatment; the state-of-the-art
/in Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer